Clinical application of GnRH-antagonists

review OA: closed public-domain-us
View on PubMed View at publisher
AI-generated summary by gemini-2.5-flash-lite, 2026-06-11

GnRH-antagonists offer advantages over GnRH-agonists and show promise for treating gynecological conditions and cancers, pending improved delivery systems and oral bioavailability.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Due to the different pharmacological mode of action, GnRH-antagonists seem to open up new avenues to hormonal treatment in several indications. Although it may be still too early to speculate about the possible end of the era of GnRH-agonists, from what is known today, the advantages of GnRH-antagonists are most evident in our opinion. When the development of sustained delivery systems may continue and be completed, the antagonists will have a major potential within benign gynecological conditions and also in the treatment of malignancies such as prostatic, mammary, endometrial or ovarian cancer. Suitable sustained delivery systems and the development of GnRH-antagonists with sufficient oral bioavailability, represent the present and future challenge for these efforts.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Gonadotropin-Releasing Hormone Clinical Trials, Phase III as Topic Endometriosis Endometriosis Female Follicle Stimulating Hormone Follicle Stimulating Hormone Gonadotropin-Releasing Hormone Humans Leiomyoma Leiomyoma Male Menotropins Menotropins Neoplasms, Hormone-Dependent Neoplasms, Hormone-Dependent Ovarian Neoplasms Ovarian Neoplasms Ovulation Induction Ovulation Induction

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-30T09:23:35.175841+00:00
pubmed
last seen: 2026-05-13T22:13:36.046895+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine